A new trading day began on Friday, with Standard BioTools Inc (NASDAQ: LAB) stock price down -2.99% from the previous day of trading, before settling in for the closing price of $1.67. LAB’s price has ranged from $1.21 to $3.16 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -0.06% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 56.74%. With a float of $361.33 million, this company’s outstanding shares have now reached $371.15 million.
In an organization with 539 employees, it is important to assess its efficiency.
Standard BioTools Inc (LAB) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Standard BioTools Inc is 2.65%, while institutional ownership is 72.37%. The most recent insider transaction that took place on Aug 08 ’24, was worth 932,601. In this transaction Director of this company bought 569,562 shares at a rate of $1.64, taking the stock ownership to the 49,000,413 shares. Before that another transaction happened on Aug 07 ’24, when Company’s Director bought 500,000 for $1.57, making the entire transaction worth $786,200. This insider now owns 48,430,821 shares in total.
Standard BioTools Inc (LAB) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 56.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.06% during the next five years compared to 8.72% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Here are Standard BioTools Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.53. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.90, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.22 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Let’s dig in a bit further. During the last 5-days, its volume was 2.71 million. That was better than the volume of 2.69 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 35.60%. Additionally, its Average True Range was 0.19.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 22.40%, which indicates a significant decrease from 34.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 205.74% in the past 14 days, which was higher than the 93.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0542, while its 200-day Moving Average is $2.3054. However, in the short run, Standard BioTools Inc’s stock first resistance to watch stands at $1.7233. Second resistance stands at $1.8267. The third major resistance level sits at $1.9133. If the price goes on to break the first support level at $1.5333, it is likely to go to the next support level at $1.4467. The third support level lies at $1.3433 if the price breaches the second support level.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
With a market capitalization of 601.26 million, the company has a total of 370,421K Shares Outstanding. Currently, annual sales are 106,340 K while annual income is -74,660 K. The company’s previous quarter sales were 37,210 K while its latest quarter income was -45,720 K.
